HEREDITARY CONNECTIVE TISSUE DISORDERS: NOMENCLATURE AND DIAGNOSTIC ALGORITHM
https://doi.org/10.17650/1818-8338-2015-1-42-49
Abstract
Hereditary connective tissue disorders (HCTDs) are a genetically and clinically diverse group of diseases, which encompasses common congenital disorders of fibrous connective tissue structures. Out of the whole variety of the clinical manifestations of NCTDs, only differentiated monogenic syndromes with the agreed guidelines for their diagnosis have been long the focus of the medical community’s attention. Many unclassified forms of the pathology (dysplasia phenotypes) have been disregarded while assessing a person’s prognosis and defining treatment policy. With no clear definition of NCTDs or their approved diagnostic algorithm, it is difficult to study their real prevalence in the population, to compare literature data, and to constructively discuss various scientific and practical aspects of this disease. Efforts to systematize individual clinical types of NCTD and to formulate their diagnostic criteria are set forth in the All-Russian Research Society Expert Committee national guidelines approved in 2009 and revised in 2012. The paper gives current views on the nomenclature of NCTDs, considers diagnostic criteria for both classified monogenic syndromes (Marfan's syndrome, Ehlers–Danlos' syndrome, MASS phenotype, primary mitral valve prolapse, joint hypermobility syndrome) and unclassified dysplasia phenotypes (MASS-like phenotype, marfanoid appearance, Ehlers–Danlos-like phenotype, benign joint hypermobility syndrome, unclassified phenotype). The above abnormalities are presented as a continuous list drawn up in the decreasing order of the degree of their clinical manifestations and prognostic value (the phenotypic continuum described by M.J. Glesby and R.E. Pyentz): from monogenic syndromes through dysplasia phenotypes to an unclassified phenotype. Emphasis is laid on the clinical NCTD identification difficulties associated with the lack of specificity of external and visceral markers of connective tissue asthenia and with the certain conventionality of NCTD diagnostic criteria. Debatable problems in the diagnosis and interpretation of the clinical significance of individual NCTDs are represented.
About the Author
A. V. Klemenov
Nizhny Novgorod Regional City Clinical Hospital Thirty; 85a Berezovskaya St., Nizhny Novgorod, 603157, Russia
Russian Federation
Russian Federation
References
1. Наследственные нарушения соединительной ткани. Российские рекомендации. Кардиоваскулярная терапия и профилактика 2009;8(S5):2–24. [Hereditary connective tissue disorders. Russian recommendations. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention 2009;8(S5):2–24. (In Russ.)].
2. Наследственные нарушения соединительной ткани в кардиологии. Диагностика и лечение. Российские рекомендации (I пересмотр). Российский кардиологический журнал 2013;1(прил 1):1–32. [Hereditary connective tissue disorders in cardiology. Diagnostics and treatment. Russian recommendations (I review). Rossiyskiy kardiologicheskiy zhurnal = Russian Cardiological Journal 2013; 1(Suppl 1):1–32. (In Russ.)].
3. Яковлев В.М., Нечаева Г.И. Системные дисплазии соединительной ткани: актуальность проблемы в клинике внутренних болезней. Сибирский медицинский журнал (Томск) 2011;26(3/2):9–12. [Yakovlev V.M., Nechayeva G.I. Systemic cases of connective tissue dysplasia: actuality of the problem in internal diseases clinic. Sibirskiy meditsinskiy zhurnal (Tomsk) = Siberian Medical Journal (Tomsk) 2011;26(3/2):9–12. (In Russ.)].
4. Кадурина Т.И., Горбунова В.Н. Дисплазия соединительной ткани. Руководство для врачей. СПб.: Элби-СПб, 2009. [Kadurina T.I., Gorbunova V.N. Connective tissue dysplasia. Manual for physicians. St. Petersburg: Elbi-SPb, 2009. (In Russ.)].
5. Cook J.R., Ramirez F. Clinical, diagnostic and therapeutic aspects of the Marfan syndrome. Adv Exp Med Biol 2014;802:77–94.
6. Gillis E., Van Laer L., Loeys B.L. Genetics of thoracic aortic aneurysm: at the crossroad of transforming growth factor-β signaling and vascular smooth muscle cell contractility. Circ Res 2013;113(3):327–40.
7. Benke K., Ágg B., Szilveszter B. et al. The role of transforming growth factor-beta in Marfan syndrome. Cardiol J 2013;20(3):227–34.
8. Franken R., den Hartog A.W., de Waard V. et al. Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndrome. Int J Cardiol 2013;168(3):2441–6.
9. Loeys B.L., Dietz H.C., Braverman A.C. et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47(7): 476–85.
10. Faivre L., Collod-Beroud G., Adès L. et al. The new Ghent criteria for Marfan syndrome: what do they change? Clin Genet 2012;81(5):433–42.
11. Radonic T., de Witte P., Groenink M. et al. Critical appraisal of the revised Ghent criteria for diagnosis of Marfan syndrome. Clin Genet 2011;80(4):346–53.
12. Земцовский Э.В., Малев Э.Г., Реева С.В. и др. Диагностика наследственных нарушений соединительной ткани. Итоги и перспективы. Российский кардиологический журнал 2013;(4):38–44. [Zemtsovskiy E.V., Malev E.G., Reyeva S.V. et al. Diagnostics of hereditary connective tissue disorders. Results and prospects. Rossiyskiy kardiologicheskiy zhurnal = Russian Cardiological Journal 2013;(4):38–44. (In Russ.)].
13. Земцовский Э.В., Малев Э.Г., Реева С.В. и др. О частоте нарушений ритма сердца и показателях его вариабельности у лиц с марфаноидной внешностью. Вестник аритмологии 2010;(59):47–52. [Zemtsovskiy E.V., Malev E.G., Reyeva S.V. et al. On the frequency of cardiac arrhythmias and their variability indicators regarding patients with marfanoid appearance. Vestnik aritmologii = Arrhythmology Herald 2010;(59):47–52. (In Russ.)].
14. Давтян К.У., Лобанов М.Ю. Роль наследственных нарушений структуры и функции соединительной ткани в развитии пароксизмов фибрилляции предсердий у больных с ишемической болезнью сердца и стенокардией напряжения. Артериальная гипертензия 2008;14(2 прил 2):5–10. [Davtyan K.U., Lobanov M.Yu. Role of hereditary violations of structure and functions of connective tissues in development of atrial fibrillation paroxysms of patients with ischemic heart disease and effort angina. Arterial'naya gipertenziya = Arterial Hypertension 2008;14(2 Suppl 2):5–10. (In Russ.)].
15. Парфенова Н.Н., Хасанова C.И., Митрофанова Л.Б. и др. Роль наследственных механизмов в возникновении склеродегенеративных поражений аортального клапана. Российский кардиологический журнал 2013;(1):50–3. [Parfyonova N.N., Khasanova S.I., Mitrofanova L.B. et al. Role of hereditary mechanisms in arising of scleradegenerative aortic valve lesions. Rossiyskiy kardiologicheskiy zhurnal = Russian Cardiological Journal 2013;(1):50–3. (In Russ.)].
16. Малев Э.Г., Желнинова Т.А., Пулит В.В. и др. Распространенность пролапса митрального клапана в российской популяции. Бюллетень Федерального центра сердца, крови и эндокринологии им. В.А. Алмазова 2011;(5):113–8. [Malev E.G., Zhelninova T.A., Pulit V.V. et al. Distribution of the mitral valve prolapse among the population of Russia. Bulleten' federal'nogo tsentra serdtsa, krovi i endokrinologii im. V.A. Almazova = Bulletin of the V.A. Almazov Federal Heart, Blood, and Endocrinology Center 2011;(5):113–8. (In Russ.)].
17. Малев Э.Г., Реева С.В., Тимофеев Е.В., Земцовский Э.В. Современные подходы к диагностике и оценке распространенности пролапса митрального клапана у лиц молодого возраста. Российский кардиологический журнал 2010;(1):35–41. [Malev E.G., Reyeva S.V., Timofeyev E.V., Zemtsovskiy E.V. Modern approaches to diagnostics and assessment of distribution of the mitral valve prolapse of young persons. Rossiyskiy kardiologicheskiy zhurnal = Russian Cardiological Journal 2010;(1):35–41. (In Russ.)].
18. Freed L.A., Benjamin E.J., Levy D. et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J Am Coll Cardiol 2002;40(7): 1298–304.
19. Khan R., Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006;118(1):10–24.
20. Beighton P., De Paepe A., Steinmann B. et al. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and EhlersDanlos Support Group (UK). Am J Med Genet 1998;77(1):31–7.
21. Morais P., Ferreira O., Magina S. et al. Classic Ehlers–Danlos syndrome: case report and brief review of literature. Acta Dermatovenerol Croat 2013;21(2): 118–22.
22. Grahame R., Bird H.A., Child A. The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). J Rheumatol 2000;27(7): 1777–9.
23. Remvig L., Jensen D.V., Ward R.C. Are diagnostic criteria for general joint hypermobility and benign joint hypermobility syndrome based on reproducible and valid tests? A review of the literature. J Rheumatol 2007;34(4):798–803.
24. Seckin U., Tur B.S., Yilmaz O. et al. The prevalence of joint hypermobility among high school students. Rheumatol Int 2005;25(4):260–3.
25. Kwon J.W., Lee W.J., Park S.B. et al. Generalized joint hypermobility in healthy female koreans: prevalence and age-related differences. Ann Rehabil Med 2013; 37(6):832–8.
26. Glesby M.J., Pyeritz R.E. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. JAMA 1989; 262(4):523–8.
Review
For citations:
Klemenov A.V. HEREDITARY CONNECTIVE TISSUE DISORDERS: NOMENCLATURE AND DIAGNOSTIC ALGORITHM. The Clinician. 2015;9(1):42-49. (In Russ.) https://doi.org/10.17650/1818-8338-2015-1-42-49
Views:
1496
Email this article 